Avita Medical
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 207
- Market Cap
- -
- Website
- http://www.avitamedical.com
- Introduction
AVITA Medical, Inc., through its subsidiaries, engages in the development and and commercialization of medical devices used in regenerative medicine. The company is headquartered in Valencia, CA.
Clinical Trials
15
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds
- Conditions
- BurnTrauma WoundFull Thickness WoundsSurgical Wound
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Avita Medical
- Target Recruit Count
- 40
- Registration Number
- NCT06787690
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸Valleywise Health, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
- Conditions
- Surgical WoundTrauma WoundAutograftsPartial-thickness BurnPartial Thickness Wounds
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Avita Medical
- Target Recruit Count
- 40
- Registration Number
- NCT06750809
- Locations
- 🇺🇸
Valleywise Health, Phoenix, Arizona, United States
🇺🇸Grady Memorial, Atlanta, Georgia, United States
🇺🇸University of Kansas, Kansas City, Kansas, United States
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
- Conditions
- Vitiligo
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Avita Medical
- Target Recruit Count
- 109
- Registration Number
- NCT05971381
- Locations
- 🇺🇸
Affiliated Dermatology, Scottsdale, Arizona, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸West Dermatology Research Center, San Diego, California, United States
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
- Conditions
- Vitiligo
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Avita Medical
- Target Recruit Count
- 25
- Registration Number
- NCT04547998
- Locations
- 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸University of California, Davis, Sacramento, California, United States
🇺🇸West Dermatology, San Diego, California, United States
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
- Conditions
- Vitiligo
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Avita Medical
- Target Recruit Count
- 5
- Registration Number
- NCT04271501
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
- Prev
- 1
- 2
- 3
- Next
News
AVITA Medical Reports 67% Revenue Growth in Q1 2025, Expands Product Portfolio
AVITA Medical reported Q1 2025 commercial revenue of $18.5 million, representing a 67% increase compared to the same period in 2024, with a strong gross profit margin of 84.7%.
AVITA Medical to Present New Clinical Data on PermeaDerm for Burn and Wound Management at ABA 2025
New clinical data demonstrates PermeaDerm's effectiveness as a temporary wound coverage solution in burn management, offering an alternative to higher-priced cadaver skin while preserving wound integrity.
AVITA Medical Launches Cohealyx: New Collagen-Based Dermal Matrix Accelerates Wound Healing
AVITA Medical has commercially launched Cohealyx, a collagen-based dermal matrix co-developed with Regenity Biosciences, designed to facilitate cellular migration and revascularization for wound healing.
AVITA Medical's RECELL GO mini Receives FDA Approval for Smaller Wound Treatment
AVITA Medical's RECELL GO mini has been approved by the FDA for treating smaller full-thickness skin defects, up to 480 square centimeters.
AVITA Medical's RECELL GO Mini Receives FDA Approval for Smaller Wound Treatment
AVITA Medical's RECELL GO mini has been approved by the FDA for treating smaller full-thickness skin defects, addressing a critical need in wound care.